CEPHALOTAXINE 4-METHYL (2R)-2-HYDROXY-2-(4-HYDROXY-4-METHYLPENTYL)BUTANEDIOATE (ESTER)
Acute Myeloid Leukemia
Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineSmall moleculePhase 3Active
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 59/ 100
- Competitive Position
- 59/ 100
Competitive context
587 Active assets in the Acute Myeloid Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Gemtuzumab M.D. Anderson Cancer Center | Phase 4 | A |
AMSACRINE University Hospital, Toulouse | Phase 4 | BBB |
Posaconazole AstraZeneca | Phase 4 | BBB |
(+)-VINCRISTINE Janssen Research & Development, LLC | Phase 3 | BBB |
AKLAVINE Chinese PLA General Hospital | Phase 4 | BB |
View all 50 →
Same molecule, other indications
CEPHALOTAXINE 4-METHYL (2R)-2-HYDROXY-2-(4-HYDROXY-4-METHYLPENTYL)BUTANEDIOATE (ESTER) is also rated in:
acute myeloid leukemia, FLT3 internal tandem duplicationDormant
B
Indicative · Phase 2
57 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →